Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2023-12-04

Development of Conformationally Restricted Negamycin Derivatives for Potent Readthrough Activity.

Omura N, Taguchi A, Kuwahara T, Hamada K, Watanabe M, Nakakuki M, Konno S, Takayama K, Taniguchi A, Nomura T, Shuto S, Hayashi Y.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.3c00424

Bibliografisk träff 2023-07-19

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.

Sutherland JJ, Yonchev D, Fekete A, Urban L.

Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9

Bibliografisk träff 2021-12-27

Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.

Kim M, Ha JH, Choi J, Kim BR, Gapsys V, Lee KO, Jee JG, Chakrabarti KS, de Groot BL, Griesinger C, Ryu KS, Lee D.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01664

Bibliografisk träff 2021-02-16

Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents.

Fan A, Sharp PP.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.0c01746

Bibliografisk träff 2020-10-22

Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS.

Mathew B, Ruiz P, Dutta S, Entrekin JT, Zhang S, Patel KD, Simmons MS, Augelli-Szafran CE, Cowell RM, Suto MJ.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.112952

Bibliografisk träff 2020-02-18

Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).

Tutone M, Pibiri I, Perriera R, Campofelice A, Culletta G, Melfi R, Pace A, Almerico AM, Lentini L.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.9b00609

Bibliografisk träff 2019-05-29

Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation.

Ankenbruck N, Kumbhare R, Naro Y, Thomas M, Gardner L, Emanuelson C, Deiters A.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.05.044

Bibliografisk träff 2018-11-21

New <i>in Vitro</i> Assay Measuring Direct Interaction of Nonsense Suppressors with the Eukaryotic Protein Synthesis Machinery.

Ng MY, Zhang H, Weil A, Singh V, Jamiolkowski R, Baradaran-Heravi A, Roberge M, Jacobson A, Friesen W, Welch E, Goldman YE, Cooperman BS.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.8b00472

Bibliografisk träff 2018-09-26

Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.

Pibiri I, Lentini L, Melfi R, Tutone M, Baldassano S, Ricco Galluzzo P, Di Leonardo A, Pace A.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.09.057

Bibliografisk träff 2016-06-29

Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.

Pibiri I, Lentini L, Tutone M, Melfi R, Pace A, Di Leonardo A.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2016.06.048

Bibliografisk träff 2014-04-13

Bis-aryloxadiazoles as effective activators of the aryl hydrocarbon receptor.

Basham KJ, Bhonde VR, Kieffer C, Mack JB, Hess M, Welm BE, Looper RE.

Bioorg Med Chem Lett · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bmcl.2014.04.013

Bibliografisk träff 2007-04-22

PTC124 targets genetic disorders caused by nonsense mutations.

Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL.

Nature · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1038/nature05756